Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Follow-Ons Off? FDA Shelves Near-Term Plans For Biologics Documents

Executive Summary

FDA's decision not to release follow-on biologics documents in the near future suggests proponents of such products may turn their focus to Congress or the courts in an effort to establish a clear regulatory framework
Advertisement

Related Content

FDA Sees Critical Path Opportunity To Address Follow-On Biologics
FDA Sees Critical Path Opportunity To Address Follow-On Biologics
Tale Of Two Pathways: Follow-On Biologics Move Forth In EU, Stall In U.S.
Tale Of Two Pathways: Follow-On Biologics Move Forth In EU, Stall In U.S.
Follow-On Biologics Pathway Unlikely Without Confirmed FDA Commissioner
Follow-On Biologics Could Gain From “Bolar Amendment” Ruling – Attorney
Omnitrope Lawsuit Could Further Delay FDA “Follow-On” Biologics Guidance
Generic Biologics Legislation Unlikely, But Issue Not Going Away
Generic Biologics Legislation Unlikely, But Issue Not Going Away
FDA Generic Biologics Short-Term Plan Includes Immunogenicity Document

Topics

Advertisement
UsernamePublicRestriction

Register

PS046406

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel